Vernal Keratoconjunctivitis (VKC) is a bilateral, usually seasonally recurrent, allergic inflammation of the conjunctiva, characterized by limbal gelatinous hypertrophy and/or upper tarsal giant conjunctival papillae.
Vernal Keratoconjunctivitis Epidemiology Segmentation in Total Major Market from 2017 to 2030
- Total Prevalent Population of Vernal Keratoconjunctivitis
- Total Diagnosed Prevalent Cases of VKC
- Gender-specific Diagnosed Prevalent Cases of VKC
- Type-specific Diagnosed Prevalent Cases of VKC
- Severity-specific Diagnosed Prevalent Cases of VKC
- Age-specific Diagnosed Prevalent Cases of VKC
Vernal Keratoconjunctivitis Epidemiology Insights
- Total prevalent population of Vernal Keratoconjunctivitis in the total market (7MM, China, Egypt, Saudi Arabia and Russia) in 2017 was 4,752,356
- The prevalence of VKC in the United States in 2017 was 65,309
- Among the EU-5 countries, the prevalent population of VKC in 2017 in Italy was 172,591 whereas in Spain, it was 15,645.
- The diagnosed prevalence was higher for males as compared to females in all the total major markets countries
- China contributes the largest share in 2017 was 2,248,706
Scope of the Report
- The Vernal Keratoconjunctivitis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
- The Vernal Keratoconjunctivitis Epidemiology Report and Model provide an overview of the risk factors and global trends of Vernal Keratoconjunctivitis in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
- The report provides insight about the historical and forecasted patient pool of Vernal Keratoconjunctivitis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
- The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
- The report assesses the disease risk and burden and highlights the unmet needs of Vernal Keratoconjunctivitis
- The report provides the segmentation of the Vernal Keratoconjunctivitis epidemiology
Request for sample pages
Table of contents
1. Key Insights
2. Executive Summary of Vernal keratoconjunctivitis (VKC)
3. Vernal keratoconjunctivitis (VKC): Epidemiology Overview at a Glance
3.1. Total Epidemiological Share (%) Distribution of VKC in 2017
3.2. Total Epidemiological Share (%) Distribution of VKC in 2030
4. Disease Background and Overview: Vernal keratoconjunctivitis (VKC)
4.1. Introduction
4.2. Signs and Symptoms of VKC
4.2.1. Signs
4.3. Causes
4.4. Risk Factors
4.5. Grades of VKC
4.6. Pathophysiology
4.6.1. Mediators in VKC
4.6.2. Cells in VKC
4.7. Histopathology
4.8. Diagnosis of VKC
5. Case Reports
5.1. Vernal Keratoconjunctivitis: A Teaching Case Report
5.2. Ocular surface disease: A case of vernal keratoconjunctivitis
5.3. Topical and Oral Cyclosporine for a Case of Severe Limbal Vernal Keratoconjunctivitis with Complete Corneal Involvement
5.4. Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab
5.5. Recalcitrant Atopic Keratoconjunctivitis in Children: A Case Report and Literature Review
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Epidemiology Methodology
7. United States Epidemiology
7.1. Assumptions and Rationale
7.2. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in the United States
7.3. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United States
7.4. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United States
7.5. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) Based on Symptoms in the United States
7.6. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United States
7.7. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United States
8. EU5 Epidemiology
8.1. Assumptions and Rationale
8.2. Germany Epidemiology
8.2.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Germany
8.2.2. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Germany
8.2.3. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Germany
8.2.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) Based on Symptoms in Germany
8.2.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Germany
8.2.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Germany
8.3. France Epidemiology
8.3.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in France
8.3.2. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in France
8.3.3. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in France
8.3.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in France
8.3.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in France
8.3.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in France
8.4. Italy Epidemiology
8.4.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Italy
8.4.2. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Italy
8.4.3. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Italy
8.4.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Italy
8.4.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Italy
8.4.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Italy
8.5. Spain Epidemiology
8.5.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Spain
8.5.2. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Spain
8.5.3. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Spain
8.5.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Spain
8.5.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Spain
8.5.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Spain
8.6. United Kingdom Epidemiology
8.6.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in the UK
8.6.2. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the UK
8.6.3. Gender-specific Prevalence of Vernal Keratoconjunctivitis (VKC) in the UK
8.6.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United Kingdom
8.6.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United Kingdom
8.6.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United Kingdom
9. Japan Epidemiology
9.1.1. Assumptions and Rationale
9.1.2. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Japan
9.1.3. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Japan
9.1.4. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Japan
9.1.5. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Japan
9.1.6. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Japan
9.1.7. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Japan
10. MEA Region Epidemiology
10.1. Assumptions and Rationale
10.2.Saudi Arabia Epidemiology
10.2.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia
10.2.2. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia
10.2.3. Gender-specific Prevalence of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia
10.2.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia
10.2.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia
10.2.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia
10.3.Egypt Epidemiology
10.3.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Egypt
10.3.2. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt
10.3.3. Gender-specific Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt
10.3.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt
10.3.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt
10.3.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt
10.4.UAE Epidemiology
10.4.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in UAE
10.4.2. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in UAE
10.4.3. Gender-specific Prevalence of Vernal Keratoconjunctivitis (VKC) in UAE
10.4.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in UAE
10.4.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in UAE
10.4.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in UAE
11. China Epidemiology
11.1. Assumptions and Rationale
11.2. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in China
11.3. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in China
11.4. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in China
11.5. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in China
11.6. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in China
11.7. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in China
12. Russia Epidemiology
12.1. Assumptions and Rationale
12.2. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Russia
12.3. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Russia
12.4. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Russia
12.5. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Russia
12.6. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Russia
12.7. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Russia
13. KOL Views
14. Appendix
14.1. Bibliography
14.2. Report Methodology
15. DelveInsight Capabilities
16. Disclaimer
17. About DelveInsight
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/